1 minute read
MEDICAL ONCOLOGY
OPEN TO RECRUITMENT — AUSTRALIA & NEW ZEALAND
Abbrev. Title
SHR3162-III-305 FUZOPRO
Protocol Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic CastrationResistant Prostate Cancer
TQB2928-I-01
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TQB2928 Injection in Patients with Advanced Solid Tumours or Hematological Malignancies
TRIO045 GO42784 ADE liDERA
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
TRIO045 GO42784 HOB liDERA
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
TRIO045 GO42784 WES liDERA
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
XL092-001 STELLAR-001
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
XL184-315 CONTACT-02
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab Vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
ABCPro
Patient Reported Outcome Measures for Individualized Symptom Evaluation and Management in Advanced Breast Cancer
